

Special Pharmaceutical Benefits Program Advisory Council
Thursday, January 28, 2021
10:00 A.M. – 12:00 P.M.
Web Conference Call

Topic/Discussion	Action
<u>Introductions, Announcements & Updates:</u> John Haines	Began 10:05 am
<p><u>Introductions:</u> SPBP Advisory Council Members, staff, and guests introduced themselves. David Givens reviewed protocols and expectations for using Skype. Kyle Fait took attendance</p> <p>Members Present: John Haines, Kathleen Brady, Margaret Hoffman-Terry, Angela Kapalko, David Koren, Leah Magagnotti, Deborah McMahan, Mimi McNichol, Meghan McNelly, Wayne Williams, Michael Witmer, Cindy Magrini, Carina Havenstrite, Rob Pompa, Art Williams</p> <p>Members Absent: Jerry Coleman, Rebecca Geiser, Michelle Collier, William Short, Evelyn Torres, Heyzabeth Vaughn</p> <p>Guests: Glenn Young, Casey Johnson, Erica Freedman, Mike Hellman, Aliah Roseman, Shanna C, Erin O’Dea, Kathryn Smith, Holly Megnin, Anne Marie McGinnis, Gina Simoncini, Shannon Pietroski, Leah Rodriguez, Nicole Risner, Michael Cullison, Debra Murdoch, Anna Barone, Morgan Curran, Diana Vargas, Kristen Welsner</p> <p>Department of Health Staff: Mari Jane Salem-Noll, Lindsey Pitten, Kendra Parry, Kyle Fait, Monisola Malomo, Michelle Schlegelmilch</p> <p>University of Pittsburgh Staff: David Givens, Scott Arrowood</p>	10:05 am – 10:13 am
<p><u>Announcements/Updates:</u> John Haines</p> <ul style="list-style-type: none"> • 2021 Meetings to be held last Thursday in January, April, July, and October. April, normally in-person meeting, will be web conference call 10am - Noon. • Cheryl Henne, Program Manager for the Care Section, has retired the first week of January and her position has been posted. • Looking for new position: SPBP program analyst. Currently awaiting for approval in HR department • Looking for Data Manager position specific to SPBP.. • All other positions currently filled. <p>SPBP Website</p> <ul style="list-style-type: none"> • New formulary posted as of January 1st, including Pfizer and Moderna Covid vaccines. • New FDA approved drug: Cabenuva is a long-acting injectable drug that has yet to be added to formulary. We are awaiting necessary drug data and 	10:14 to 10:43 am

<p>information to proceed with adding it. Comment from member: Cabenuva may only be available through ViiV Healthcare themselves. The oral lead-in will be provided by ViiV directly at no cost to patient. If this is true it would not be added to formulary, but would provided at no cost. Currently expected to be available mid-February. Will need to be mindful of patients who may have difficulty working directly with company Covered lab test updated yearly, most recently on Sept. 1</p> <ul style="list-style-type: none"> • Posted: 2021 Medicare Part C advantage plan and Part D drug premium payment list. • Received updated federal poverty limit guidelines and submitted for posting, the SPBP enrollment income limit (\$64,400 individual with \$22,700 allowance per spouse or dependent). <p>Medicaid Back billing process:</p> <ul style="list-style-type: none"> • Implementation began January, which satisfies one of the HRSA site visit citations. • Using a Pharmacy void rebill process, first group of pharmacies have been notified. Estimated \$121,000 will be reclaimed for SPBP. This will occur on a quarterly basis. • Refill limits were lifted but expect to be turn on again in February; however, there is a process to override. The patient would need to contact SPBP. There were pockets of early refills and over utilization a few years ago (early 2010s, possibly), which smoothed out after the limits were enacted. Based on conversation among the council members, the 85% utilization amount will be lowered to 75%. SPBP refill limits only factor if there is no other payer; i.e. it defaults to the primary payer (for example, Medicare or employer plan). One member mentioned they contractually cannot lower the utilization amount so they will keep the limits turned off. Three other members voiced agreement with 75%. Motion made to lower threshold. Seconded by Angela and all in favor. Passed unanimously. • David Givens – announcement: HIV home testing program has been in development in collaboration with Penn State. Now being implemented: GetMyHIVTest.com 	
<p><u>Approval of previous minutes</u></p> <p>No corrections or changes to minutes. Minutes, that were sent out in advance, are approved.</p>	10:44 to 10:46 am
<p><u>Data & Quality Management Update: John Haines</u></p> <ul style="list-style-type: none"> • Previous Ryan White year: 9,000 unique clients which was an increase about 5% from the prior year. • Number pulled for January 15 shows 5,783 current active clients. 	10:47 to 10:55 am

<ul style="list-style-type: none"> • Prior Quarter October to December 2020: <ul style="list-style-type: none"> ○ Average age: 55 ○ Paid 60,000 claims for medications. Up 16% from prior year. ○ 3.3 claims per member per month ○ Average cost per claim: \$375 • BIKTARVY is top drug followed by GENVOYA, and TRIUMEQ • Top claims are HIV drugs, hypertension dyslipidemia, antidepressants • Weekly Expenditures: There continues a drop of active clients since April 2020 	
<p><u>Outreach Initiatives & MAI Update:</u> Kyle Fait</p> <p>Minority AIDS Initiative Update (MAI)</p> <ul style="list-style-type: none"> • Oct to Dec Quarter: 753 received outreach services; 464 received health education and risk reduction services; 86 clients newly diagnosed or re-enrolled; 87 clients linked to medical care 270 newly diagnosed; 120 linked to medical care; 243 attend 2+ medical appts; 77 achieved undetectable viral load. • Outreach services: 76% minorities; 38% that were Caucasian • Health education risk reduction: 66% minorities and 34% • Challenges with telehealth included increase lag time with lab work. • Learning Sessions cancelled for in-person due to COVID-19. Virtual sessions continued through the fall and covered COVID, tele-health trends, prison, mental health self-care and reopening strategy. Next session will be in April. • MAI Provider Spotlight: Amaree McGinnis, program coordinator of the Philadelphia linkage program. Stopped visiting in March 2020 at beginning of pandemic. In June 2020 began partial schedule in office and remote working. Went back into jails in August. Have at least 2 team members in office at time. Still doing telehealth but also keeping safety protocols so may also be able to see client in office. <p>5 year Spend Plan</p> <ul style="list-style-type: none"> • PA NEDSS upgrade expected at full implementation Jan 3, 2022 <ul style="list-style-type: none"> ○ Training plan; Data Collection ongoing; Cloud hosting completed; Data sharing agreements with Philly • Annual HIV conference: original plan was in-person in September but instead hope to have it in the later half of 2021. <p>HPG activity: Next virtual meeting is Feb 10 -11.</p> <ul style="list-style-type: none"> • Member Orientation • Subcommittees will convene. • Priority Setting. 	<p>10:55 to 11:15am</p>
<p><u>Fiscal Update:</u> Lindsey Pitten</p>	<p>11:16 to 11:18 am</p>

Funding	FY 2018-19	Expenditures	FY 2018-19
SPBP Grant Award	\$28,064,078	Drug Claims	\$75,448,001
Part B Grant Award	\$10,617,820	Claims Admin	\$2,625,876
Carry-over 2017	\$10,074,578	Medicare Claims (Parts C & D)	\$1,155,283
Rebates	\$65,806,768	RW Grant Admin	\$3,778,709
TPLs	\$3,508,447	RW Lab Testing	\$310,067
State Appropriation	\$0	Regional Expenditures	\$26,022,374
Total Funding	\$118,071,691	Total Expenditures	\$109,340,309
		Carry-over	\$8,731,382

Funding	FY 2019-20	Expenditures	FY 2019-20
SPBP Grant Award	\$27,711,308	Drug Claims	\$82,828,198
Part B Grant Award	\$10,726,651	Claims Admin	\$331,899
Carry-over 2018	\$8,731,380	Medicare Claims (Parts C & D)	\$164,878
Rebates	\$68,589,324	RW Grant Admin	\$2,812,074
TPLs	\$8,778,646	RW Lab Testing	\$358,725
State Appropriation	\$0	Regional Expenditures	\$2,887,356
Total Funding	\$124,537,308	Total Expenditures	\$89,383,130

Funding	FY 2020-21	Expenditures	FY 2020-21
SPBP Grant Award	\$26,832,592	Drug Claims	\$37,234,518
Part B Grant Award	\$10,648,813	Claims Admin	\$833,369
Anticipated Carry-over 2019	\$6,574,999	Medicare Claims (Parts C & D)	\$358,674
Rebates	\$19,837,098	RW Grant Admin** **not updated since last meeting	\$1,082,648
TPLs	\$1,331,383	RW Lab Testing** **not updated since last meeting	\$0
State Appropriation	\$0	Regional Expenditures** **not updated since last meeting	\$1,887,168
Total Funding	\$65,224,886	Total Expenditures	\$41,396,377

Clinical Quality Management Plan: Michelle Schlegelmilch

11:18 to 11:23 am

- Thank you for member input. Plan was provided to regional grantees, January 19th for review and discussion. CQM workgroup under the HPG looks at historical data to identify and prioritize potential opportunities for improvement.
- Workgroup comprised of self, John Haines, Steven Wimmer, Wedny Sweigert, Robert Pompa, and Michael Whitmer. Next scheduled meeting in February.
- Quality Measure Categories are: outpatient ambulatory health services, medical case management, food bank, housing, education, and risk reduction, and ADAP.

- Regional Grantees are also required to have at least one quality improvement project, prior to their annual site visit.
- SPBPAC had opportunity to review and give feedback to draft of plan which has since been finalized through executive review at DOH.

Drug Additions and Exclusions: Margaret Hoffman-Terry

11:24 to 11:29 am

Note: COVID vaccines already added

Add:

DRUG NAME	DESCRIPTION	FORMULARY DESCRIPTION	COMMENTS
LAMPIT	nifurtimox	ANTIBIOTICS	Treatment of American trypanosomiasis infection (Chagas disease). Oral tablet. All other anti infectives are covered.
FINTEPLA	fenfluramine	ANTICONVULSANTS	Treatment of Dravet syndrome-associated seizures. Oral solution. All other anticonvulsants are covered.
BARHEMSYS	amisulpride	ANTIEMETICS	Prevention of post-operative nausea and vomiting. IV solution. All other antiemetics are covered.
ECONASIL	econazole	ANTIFUNGAL AGENTS	Treatment of fungal infections. Topical cream. All other antifungals are covered.
ZOLPAK	econazole	ANTIFUNGAL AGENTS	Treatment of fungal infections. Topical cream. All other antifungals are covered.
BLENREP	belantamab mafodotin-blmf	ANTINEOPLASTIC AGENTS	Treatment of mulple myeloma. IV solution. All other antineoplastics are covered.
GAVRETO	pralsetinib	ANTINEOPLASTIC AGENTS	Treatment of non-small cell lung cancer and thyroid cancer. Oral capsule. All other antineoplastics are covered.
INQOVI	decitabine	ANTINEOPLASTIC AGENTS	Treatment of myelodysplastic syndromes. Oral tablet. All other antineoplastics are covered.
MONJUVI	tafasitamab-cxix	ANTINEOPLASTIC AGENTS	Treatment of diffuse large B-cell lymphoma. IV solution. All other antineoplastics are covered.
ONUREG	azacitidine	ANTINEOPLASTIC AGENTS	Treatment of acute myeloid leukemia. Oral tablet. All other antineoplastics are covered.
PHESGO	pertuzumab-zzxf	ANTINEOPLASTIC AGENTS	Treatment of breast cancer. Subcutaneous injection solution. All other antineoplastics are covered.
TECARTUS	brexucabtagene autoleucl	ANTINEOPLASTIC AGENTS	Treatment of mantle cell lymphoma. IV suspension. All other antineoplastics are covered.
ZEPZELCA	lurbicetedin	ANTINEOPLASTIC AGENTS	Treatment of small cell lung cancer. IV solution. All other antineoplastics are covered.
TPOXX (NATIONAL STOCKPILE)	tecovirimat	ANTIVIRAL AGENTS	Treatment of smallpox. Oral capsule. All other antivirals are covered.
BREZTRI AEROSPHERE	budesonide	ASTHMA/COPD AGENTS	Treatment of COPD. Inhalation aerosol. All other COPD agents are covered.
TWIRLA	levonorgestrel	CONTRACEPTIVES	Indicated for contraception. Transdermal patch. All other contraceptives are covered.
GIMOTI	metoclopramide	GASTROINTESTINAL AGENTS	Treatment of diabetic gastroparesis. Nasal solution. All other GI agents are covered.
HEMADY	dexamethasone	GLUCOCORTICOIDS	Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases. Oral tablet. All other corticosteroids are covered.
ORTIKOS	budesonide	GLUCOCORTICOIDS	Treatment of Crohn disease. Oral capsule. All other corticosteroids are covered.
BAFIERTAM	monomethyl fumarate	MULTIPLE SCLEROSIS AGENTS	Treatment of MS. Oral capsule delayed release. All other MS agents are covered.
KESIMPTA PEN	ofatumumab	MULTIPLE SCLEROSIS AGENTS	Treatment of MS. Subcutaneous injection solution. All other MS agents are covered.
MENQUADFI	meningococcal vac A.C.Y, W-135.cc	VACCINES, BIOLOGICALS AND TOXIDS	Prevention of meningococcal disease. IM injection. All other vaccines are covered.

Exclude:

DRUG NAME	DESCRIPTION	COMMENTS
BYNFEZIA	octreotide	Treatment of acromegaly. GH and somatostatin analogs are not covered. Subcutaneous pen injection.
ENSPRYNG	satralizumab-mwge	Treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 (AQP4) antibody positive. Subcutaneous solution pre-filled syringe.
LIDOTIN	gabapentin	Gabapentin kit. Gabapentin covered as individual agent, but not part of a kit.
LIPRITIN II	gabapentin	Gabapentin kit. Gabapentin covered as individual agent, but not part of a kit.
MYCAPSSA	octreotide	Treatment of acromegaly. GH and somatostatin analogs are not covered. Oral capsule delayed release.
UPLIZNA	inebilizumab-cdon	Treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 (AQP4) antibody positive. IV solution

- Motion passed to accept additions and exclusions. None opposed.

No Subcommittee Reposts

11:32 am

Adjourn